Sen-Jam Pharmaceutical

07/24/2025

“Longevity is a bigger market opportunity than obesity.” – Jay Olson, Oppenheimer

The same way GLP-1s exploded the obesity market into a Wall Street darling, longevity is next. Jay Olson nails it: we’re going from theory to therapy right now—and early investors have a rare moment to get in before the street catches on.

At 15:50, Jay spotlights Sen-Jam’s platform—a patented, de-risked combo therapy repurposing two proven drugs, squarely positioned in metabolic restoration, a key subsector he calls “king.” 👑

“This is one of the most exciting but least understood investment areas today… the opportunity is NOW.”

🎧 Listen to the full 20-min podcast: https://lnkd.in/e7KbsTkj

Own an Early Piece of the Longevity Play
🔗 Invest now https://bit.ly/44b0gne

07/02/2025

Chronic inflammation is quietly fueling nearly every major disease—and draining trillions from the global economy.
For decades, pharma’s answer has been symptom management, side effects, immunosuppression and stagnation.
We built a new model. A precision platform that restores the body, targets what others miss, and flips the entire system on its head.
This isn’t just a biotech breakthrough. It’s a health rebellion—fueled not by corporate VC titans, but by people who believe in ending sickcare for good.
🔥 Watch us flip the script.
📈 Invest in the movement → http://bit.ly/44b0gne

04/04/2025

What if the secret to longevity isn’t more treatment—but smarter prevention? 🧬

Jackie Iversen, RPh MS of takes the stage at to share how inflammation modulation could be the key to unlocking true vitality.

03/21/2025

🏀 MARCH MADNESS MONEY PLAY! 🏀
We’re rallying 2,000 fans to each invest $1,000 to help us CLINCH the CHAMPIONSHIP for SJP-001 — the world’s first and only FDA-approved alcohol overindulgence prevention pill (coming soon).

Whether you're crushing beers, betting brackets, or just in it for the wings — we’ve got the hangover game plan.

💥 Watch. Laugh. Share. Invest.
💰 👉 bbit.ly/31mYAcD

Let’s win big for your morning-after self. 🍻

03/16/2025

🔥 It’s time we rethink overindulgence.
Hangovers and food comas aren’t just bad mornings—they’re metabolic inflammation. And that means we don’t need a Band-Aid, we need a breakthrough.
🚀 Enter Sen-Jam: the first-ever FDA-approved hangover prevention pill. Modern times demand modern solutions, and OTC has never had it so good.
🏀 Get in before the buzzer! We need 2,000 investors at $1,000+
https://bit.ly/4ii5aTR
Help this game-changer clinch this game-changing moment. And yes, there’s an exclusive Sen-Jam baseball hat waiting for those who take the shot.
⏳ It’s time to invest in the future of feeling good.
💰 Invest Now

03/10/2025

🏀 WAKE UP A WINNER! 🍻
Take your shot at a game-changing investment! Sen-Jam is developing what could be the first FDA-approved hangover prevention pill https://bit.ly/4ii5aTR
🔥 2,000 fans. $1K each. One billion dollar opportunity!
PLUS Invest $1K+ score our ‘Good Karma Pharma’ hat!

Sen-Jam Pharmaceutical is on a mission to help people live side-effect free. We develop consumer healthcare products that help people stay strong by mitigating common side effects from medicines and everyday living.

Sen-Jam's Global scientists have developed a multi-indication patent and FDA-pending product for the prevention of pain and flu-like symptoms for indications not currently being addressed by the FDA OTC Drug Monograph.

It's time for a stronger, more resilient world, free of side-effects and filled with living remarkably.

02/13/2025

⏰ 3 DAYS LEFT! Don't miss Sen-Jam Pharmaceutical's premier investor incentives. We're transforming healthcare, and your opportunity awaits.
https://bit.ly/31mYAcD to learn more.

01/28/2025

🚀 Tomorrow at 2 PM EST: Sen-Jam’s 2025 Growth Webinar
Get insider insights on:
✅ JPMorgan Conference Update
✅ PAIR Technology breakthroughs
✅ Promising SJP-002C trial results
✅ Advances in SJP-001 & new patents
✨ Don’t miss this chance to hear from our leadership team!
👉 Register Now https://bit.ly/4jnmlo5

01/26/2025

✨ Big News for Sen-Jam Pharmaceutical! ✨
Our groundbreaking hangover therapeutic, SJP-001, has been spotlighted in a newly published paper linking frequent alcohol consumption and hangovers to chronic inflammation and heightened cancer risks. Aligning with the recent Advisory issued by the US Surgeon General.
With the first FDA-approved hangover remedy in development, we’re tackling both immediate symptoms and long-term health risks. 🌍💡
Backed by strong clinical data and a $6B market opportunity by 2030, SJP-001 is positioned to make waves in public health and investor portfolios alike.
Learn more about this transformative opportunity: https://wefunder.com/updates/179036

01/23/2025

📢 Important Update: Phase 2 Clinical Trial Results for SJP-002C Validates our PAIR Technology Platform
Promising safety data and efficacy signals for upper respiratory infections, supporting our innovative PAIR platform tech
Read update👇
https://wefunder.com/updates/178961

01/22/2025

🚨 Breaking News! 🚨
We’re thrilled to announce our financial and strategic partnership with 5 Horizons Capital! 🤝 -- a premier investment firm known for its expertise in identifying and supporting disruptive healthcare innovations. You can read more about this here: https://lnkd.in/g7_aiKyM

01/21/2025

🌟 Transforming Inflammatory Care 🌟
Sen-Jam Pharmaceutical’s PAIR Technology is rewriting the rules of anti-inflammatory medicine. Fresh from the JPMorgan Healthcare Conference and backed by Phase 2 clinical trial success, our revolutionary platform promises to address systemic inflammation in ways previously thought impossible.
Join us in pioneering a new era of healthspan preservation and see why PAIR is positioned to be the fifth transformative moment in anti-inflammatory medicine.
read here: https://lnkd.in/gfmrnz6N
📢 Don’t miss our exclusive webinar on January 29 at 2 PM EST, where we’ll share insights from our latest breakthroughs.
👉 Register here: https://bit.ly/4jnmlo5
Be part of the revolution. 🌎 hashtag hashtag hashtag